Healthcare / BiotechnologyTokyo
$140.00
-3.00 (-2.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-548.4M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.8%
↓Gross Margin
39.8%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.9%
FCF CAGR
—
FCF margin
-226.8%
FCF / Net income
1.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $677.3M · net income $-833.7M · FCF $-1.54B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $677.3M | $677.3M | $305.6M | $112.9M | $554.4M |
| Net Income | $-833.7M | $-833.7M | $-1.05B | $-526.9M | $73.0M |
| EBITDA | $-774.5M | $-774.5M | $-782.4M | $-488.1M | $67.9M |
| EPS | — | — | -33.53 | -19.09 | 2.06 |
| Gross Margin | 39.8% | 39.8% | 52.5% | 71.1% | 96.5% |
| Operating Margin | -114.3% | -114.3% | -256.0% | -440.0% | 12.0% |
| Net Margin | -123.1% | -123.1% | -343.4% | -466.6% | 13.2% |
| Balance Sheet | |||||
| Current Ratio | 5.66 | 5.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.54B | $-1.54B | $-61.6M | $-548.4M | $97.2M |
| Returns | |||||
| ROE | -30.8% | -30.8% | -30.0% | -45.9% | 4.4% |
| Valuation | |||||
| P/B | 1.90 | 1.90 | 3.65 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 121.6% | 121.6% | 170.6% | -79.6% | — |
| EPS Growth | — | — | -75.6% | -1025.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-33.53 → n/d
Residual
-46.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.